FDA convened this weeks meeting to discuss seven unapproved peptides that are under review for various medical conditions, including ulcerative colitis, migraines and opioid addiction
All study participants were randomly assigned to an experimental treatment group that received subcutaneous injection of cagrilintide, once-weekly, in doses of either 0.3, 0.6, 1.2, 2.4, or 4.5 mg, as well as a one-daily 3.0 mg dose of liraglutide, and a volume matched placebo for control purposes
Twice daily application is usually unnecessary, the enhanced permeability means you're getting adequate penetration from single application
Chachlaki K, Garthwaite J, Prevot V
The table below distills the mechanism, evidence, and regulatory differences covered throughout this guide into a single reference point